Page 2 - Today Biogen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS

Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesTimothy millerWalter gilbertCharles weissmannHeinz schallerAlfred sandrock jrAshleigh kossMike henckeKenneth murrayHead of researchIonis pharmaceuticals incBiogen incWashington university school of medicineAmerican neurological associationExchange commission

Biogen Inc : Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS to be Presented at the American Neurological Association Annual Meeting

CAMBRIDGE, Mass., Oct. 14, 2021Inc. (Nasdaq: BIIB) today announced topline results from its pivotal Phase 3 VALOR study of tofersen (BIIB067), an investigational antisense oligonucleotide (ASO) drug being

United kingdomUnited statesAshleigh kossTimothy millerMike henckeHeinz schallerWalter gilbertCharles weissmannKenneth murrayIonis pharmaceuticals incWashington university school of medicineAmerican neurological associationWashington university schoolIonis pharmaceuticalsNobel prizeToday biogen

Biogen Inc : New Data at ECTRIMS 2021 Highlight Biogen s Focus on Patient-Centered Outcomes and Improving the MS Patient Experience

Full analysis of Phase 3b NOVA study provides insights on efficacy of every six-week dosing with natalizumab as compared to the approved every four-week dosingReal-world analysis shows significantly lower

United statesUnited kingdomJohn foleyMaha radhakrishnanCharles weissmannWalter gilbertHeinz schallerZhovtis ryersonAshleigh kossRobert naismithMike henckeKenneth murrayAmerican academy of neurology virtual annual meetingProgram databaseWashington university school of medicineExchange commission

Biogen Inc : New MS PATHS Data at ECTRIMS 2021 Confirm Biogen s Disease-Modifying Therapies Do Not Reduce Antibody Response to COVID-19 Vaccines in People with Multiple Sclerosis

MS PATHS data indicate that 100 percent of people with MS treated with natalizumab, interferons or fumarates achieved an antibody response following COVID-19 vaccinationData from this analysis also suggest

United kingdomUnited statesJeffrey cohenMaha radhakrishnanWalter gilbertCharles weissmannHeinz schallerAshleigh kossMike henckeDiroximel fumaratePeginterferon betaKenneth murrayExchange commissionAdministration in black african americanPartners advancing technologyResearch in multiple sclerosis

Eisai Initiates Rolling Submission To The U S FDA For Biologics License Application Of Lecanemab (BAN2401) For Early Alzheimer s Disease Under The Accelerated Approval Pathway

Eisai Initiates Rolling Submission To The U S FDA For Biologics License Application Of Lecanemab (BAN2401) For Early Alzheimer s Disease Under The Accelerated Approval Pathway
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomHaruo naitoCharles weissmannWalter gilbertHeinz schallerLibby holmanMichel vounatsosAshleigh kossMike henckeJeffrey cummingsKenneth murrayPrnewswire eisai co ltdInvestor relations departmentBiogen incUniversity of nevada las vegas